Phase I Evaluation of Safety and Immunogenicity of DNA Vaccine N-pVAX1 in Crimean Congo Hemorrhagic Fever Patients

The primary objective of this Phase I study is to evaluate the **safety** and **immunogenicity** of the DNA vaccine N-pVAX1 in individuals at risk for **Crimean Congo Hemorrhagic Fever**. This evaluation is clinically relevant as it aims to determine the vaccine's potential to induce an immune response without causing adverse effects, which is crucial for the development of effective preventive measures against this severe viral disease.

The clinical trial involves participants diagnosed with **Crimean Congo Hemorrhagic Fever**. The study population includes both male and female subjects, with an age range categorized under code "3". The trial population was selected to include a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Information on lifestyle considerations such as diet, physical activity, or habits is not available. The sponsor has not disclosed key inclusion or exclusion criteria for this study.

The clinical trial is designed to evaluate the **safety** and **immunogenicity** of a DNA vaccine, N-pVAX1, targeting **Crimean Congo Hemorrhagic Fever**. This is a Phase I trial, which is the initial phase in clinical research, focusing on assessing the safety profile of the investigational vaccine. The trial employs a randomized, double-blind, and controlled design to ensure unbiased results and to maintain the integrity of the data collected. The estimated duration of the trial spans from April 1, 2024, to December 31, 2025, allowing for comprehensive data collection and analysis.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a thorough assessment to ensure participants meet the necessary health standards for trial inclusion. Following the screening, participants will attend scheduled follow-up visits, which are critical for monitoring the vaccine's effects and collecting data on any adverse events or immune responses. These visits will occur at regular intervals throughout the trial period. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the vaccine's safety and immunogenicity.

The expected length of participant involvement is aligned with the trial's overall duration, with specific timelines for each phase of the study. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study protocols, or withdrawal of consent by the participant. The trial is structured to ensure participant safety and the collection of high-quality data, contributing to the understanding of the vaccine's potential in preventing **Crimean Congo Hemorrhagic Fever**.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, focusing on initial safety and efficacy assessments. The estimated recruitment start date is April 1, 2024, with an anticipated end date of December 31, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve the collection of preliminary data on the drug's effects, which may include **biomarker** levels or other relevant clinical measures. The trial will likely employ validated scales and laboratory tests to gather data at predetermined intervals throughout the study period. The analysis of these parameters will be conducted to determine the initial efficacy profile of the investigational product. The trial's design and methodology will adhere to standard clinical research protocols to ensure the reliability and validity of the findings.